Evaluation of hepatitis B virus and Hepatitis C virus frequency in hemodialysis patients

Aim: This study aimed to investigate the prevalence of the hepatitis B virus and hepatitis C virus in patients undergoing hemodialysisin Karabuk city.Material and Methods: For patients presented to the Karabuk University Training and Research Hospital for hemodialysis betweenJanuary 2016 and December 2018, HBsAg, anti-HBs, and anti-HCV assays were conducted using the chemiluminescence methodand HBV DNA, HCV RNA and HCV genotyping tests were conducted using real-time polymerase chain reaction. The data wasretrospectively evaluated.Results: Of 345 patients undergoing hemodialysis, 211 (61.2%) were male and 134 (38.8%) were female. The mean ageof the patients was 62 (15–96) years. Moreover, 0.9% (n = 3) of patients were HBsAg positive and 4.3% (n = 15) wereanti-HCV positive. Three patients with HBsAg positivity were also HBV DNA positive. Of the 15 patients who were antiHCV positive, 12 were also HCV RNA positive. Of these, eight patients had the HCV genotype 1b and four patients hadthe genotype 4. Anti-HBs seropositivity was detected in 65.8% of patients. The highest Anti-HBs seropositivity rate wasobserved in patients aged

PDF

___

1. Jefferies M, Rauff B, Rashid H, et al. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018;6:589-99.
2. Kayar Y, Dertli R. Factors affecting hepatitis B immunization in celiac disease. Ann Med Res 2019;26:1478-83.
3. Kamal IMA, Mahdi BM. Seroprevalence occurrence of viral hepatitis and HIV among hemodialysis patients. Ann Med Surg 2018;29:1-4.
4. Roushan MRH, Farokhtabar S, Bayani M, et al. Epidemiological Aspects of Hepatitis B and C and Human Immunodeficiency Viruses Among Hemodialysis Patients in Mazandaran Province, Iran. Nephrourol Mon 2016;8:37878.
5. Demirbakan H, Daglar D, Ergani A, et al. Investigation of Hepatitis B and Hepatitis C Virus Infections by Serological and Molecular Methods in Hemodialysis Patients. Mikrobiyol Bul 2014;48:143-50.
6. Ayub MA, Bacci MR, Fonseca FLA, et al. Hemodialysis and hepatitis B vaccination: a challenge to physicians. Int J Gen Med 2014;7:109-14.
7. Temiz H, Kaya S, Berekatoglu N, et al. The Evaluation of the Seroprevalence of HBV, HCV and HIV Infections and the Assessment of Antibody Response to Hepatitis B Vaccination in Hemodialysis Patients. Viral Hepat J 2013;19:140-3.
8. Cordeiro VM, Martins BCT, Teles SA, et al. Decline in hepatitis B and C prevalence among hemodialysis patients in Tocantins. Northern Brazil. Rev Inst Med trop S Paulo 2018;60:36.
9. Fabrizi F. Hepatitis C virus infection and dialysis: 2012 update. ISRN Nephrol 2013;2013:159760.
10. Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J Hepatol 2015;7:885-95.
11. Hepatitis B. World Health Organisation (WHO). https://www.who.int/news-room/fact-sheets/detail/ hepatitis-b access date 18 July 2019.
12. Akarca US. Chronic hepatitis B. A guideline to diagnosis, approach, management, and follow-up 2007. Turkish Association for the Study of Liver. Turk J Gastroenterol 2008;19:207-30.
13. Ege B, Kucuk AOA, Koparal M. Investigation preoperative seroprevalence of HBsAg, anti-HBS, anti-HCV, anti-HIV and vaccination level of patients undergoing dental surgical procedure under local anesthesia. Ann Med Res 2019;26:1503-7.
14. Seyahi N. Türk Nefroloji Derneği 2017 yılı Türk Böbrek Kayıt Sistemi. http://www.nefroloji.org.tr/folders/file/ TND-2017-Kayit-Sistemi-Verileri.pdf access date 20 July 2019.
15. Eser Karlidag G, Kuçuksu M, Demir M. HBsAg, Anti-HBs, Anti-HCV and HIV Seroprevalence in Hemodialysis Patients in Elazığ Province. Viral Hepat J 2018;24:53-6.
16. Kizilates F, Berk H, Coban M, et al. Seroprevalence of hepatitis B and C virus in patientswho undergo hemodialysis in Antalya province, Turkey. Asian Biomed 2016;10:339-44.
17. Guimaraes MNC, Facincani T, Santos SSD. Hepatitis B status in hemodialysis patients. Arq Gastroenterol 2017;54:356-8.
18. Savcı U, Bulut Y. Polymerase chain reaction with investigation of occult Hepatitis B infection in hemodialysis patients. Turk J Clin Lab 2015;6:19-23.
19. Hepatitis C. World Health Organization (WHO). https://www.who.int/news-room/fact-sheets/detail/ hepatitis-c access date 18 July 2019.
20. Odemis I, Kose S, Tatar B, et al. Hepatitis A, B, C and HIV seroprevalence among young health care workers: A cross-sectional study. Behcet Uz Cocuk Hast Derg 2018;8:8-14.
21. Tozun N, Ozdogan OC, Cakaloglu Y, et al. A Nationwide Prevalence Study and Risk Factors for Hepatitis A, B, C and D Infections in Turkey. Boston: AASLD National Meeting in Boston; 2010. p. A789.
22. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004;20:1271-7.
23. Selcuk H, Kanbay M, Korkmaz M, et al. Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment. Dig Dis Sci 2006;51:1420-5.
24. Perez RM, Ferraz ML, Figueiredo MS, et al. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003;69:489-94.
25. Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015;7:2792-810.
26. Kirisci O, Caliskan A. The Predominance of Genotype 3 in Hepatitis C Virus in the Province of Kahramanmaras, Turkey/Genotype Distribution of Syrian Refugee Patients with Hepatitis C in Kahramanmaras Province. Jundishapur J Microbiol. 2019;12:80872.
27. Mohamed NA, Zainol RZ, Wong KK, et al. Hepatitis C genotype and associated risks factors of patients at University Kebangsaan Malaysia Medical Centre. Pak J Med Sci 2013;29:1142-6.
28. Jain M, Chakravarti A, Kar P. Clinical significance of isolated anti-hbc positivity in cases of chronic liver disease in new delhi, India. J Glob Infect Dis 2009;1:29-32.